Earnings Releases·Nov 9, 2026, 4:07 PM ET

CervoMed — Third Quarter 2026 Earnings Summary

Net loss for the quarter ended September 30, 2026, was approximately $5.9 million, a reduction from $7.7 million in the prior year period, driven by lower R&D expenses of $3.7 million versus $6.0 million, partially offset by the absence of grant revenue which totaled $0 compared to $0.3 million previously.
Cash and marketable securities decreased to $19.6 million as of September 30, 2026, from $20.9 million at year-end 2025, with current resources projected to fund operations and capital expenditures through Q3 2027.
The Company is actively seeking a strategic partnership to advance neflamapimod into a Phase 3 trial for Dementia with Lewy Bodies (DLB) and is evaluating financing alternatives to support this transition.
Key clinical milestones include expected top-line data from the RESTORE stroke trial by end of 2026, 24-week biomarker data for the nfvPPA trial in November 2026, and initial dosing for the EXPERTS-ALS trial in Q1 2027.
Regulatory progress includes FDA removal of a prior drug exposure limit for neflamapimod and the receipt of a UK Innovation Passport designation to support accelerated market access for DLB.